CN101959420A - 免疫原性组合物 - Google Patents

免疫原性组合物 Download PDF

Info

Publication number
CN101959420A
CN101959420A CN2008800164220A CN200880016422A CN101959420A CN 101959420 A CN101959420 A CN 101959420A CN 2008800164220 A CN2008800164220 A CN 2008800164220A CN 200880016422 A CN200880016422 A CN 200880016422A CN 101959420 A CN101959420 A CN 101959420A
Authority
CN
China
Prior art keywords
antigen
viral vector
virus
immunogenic composition
leu
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2008800164220A
Other languages
English (en)
Chinese (zh)
Inventor
西蒙·德拉佩
阿德里安·伊尔
费尔加尔·伊尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Imaxio SA
Oxford University Innovation Ltd
Original Assignee
Imaxio SA
Oxford University Innovation Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Imaxio SA, Oxford University Innovation Ltd filed Critical Imaxio SA
Publication of CN101959420A publication Critical patent/CN101959420A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • A61K39/015—Hemosporidia antigens, e.g. Plasmodium antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN2008800164220A 2007-04-10 2008-04-10 免疫原性组合物 Pending CN101959420A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0706912.3A GB0706912D0 (en) 2007-04-10 2007-04-10 Novel viral vaccines
GB0706912.3 2007-04-10
PCT/GB2008/001271 WO2008122817A2 (en) 2007-04-10 2008-04-10 Immunogenic compositions

Publications (1)

Publication Number Publication Date
CN101959420A true CN101959420A (zh) 2011-01-26

Family

ID=38091118

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2008800164220A Pending CN101959420A (zh) 2007-04-10 2008-04-10 免疫原性组合物

Country Status (8)

Country Link
US (1) US20110064768A1 (https=)
EP (1) EP2155242A2 (https=)
JP (1) JP2010523138A (https=)
CN (1) CN101959420A (https=)
AU (1) AU2008235315A1 (https=)
CA (1) CA2683117A1 (https=)
GB (1) GB0706912D0 (https=)
WO (1) WO2008122817A2 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105744950A (zh) * 2013-11-05 2016-07-06 巴法里安诺迪克有限公司 用于使用表达肿瘤抗原的痘病毒和免疫检查点抑制剂的拮抗剂和/或激动剂治疗癌症的组合疗法

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0719509D0 (en) * 2007-10-05 2007-11-14 Isis Innovation Molecular adjuvant
WO2010127420A1 (pt) * 2009-05-05 2010-11-11 Universidade Federal De Minas Gerais - Ufmg Sequências geneticamente modificadas de antígenos de plasmodium vivax
GB0918154D0 (en) 2009-10-16 2009-12-02 Isis Innovation Mycobacterial vaccines
EP2557089A2 (en) * 2011-07-15 2013-02-13 Fundació Institut d'Investigació Biomèdica de Bellvitge (IDIBELL) Compositions and methods for immunomodulation
EP2931896B1 (en) 2012-12-11 2019-01-16 Osivax SAS Modified coiled coil type proteins having improved properties
EP3188752A2 (en) * 2014-09-03 2017-07-12 Bavarian Nordic A/S Recombinant modified vaccinia virus ankara (mva) filovirus vaccine

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2678797A (en) * 1996-04-22 1997-11-12 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Heterologous boosting immunizations
GB9711957D0 (en) * 1997-06-09 1997-08-06 Isis Innovation Methods and reagents for vaccination
GB9922361D0 (en) * 1999-09-21 1999-11-24 Isis Innovation Generating an immune response to an antigen
CA2467486A1 (en) * 2001-11-30 2003-06-12 Isis Innovation Limited Vaccine
WO2003076598A2 (en) * 2002-03-13 2003-09-18 Merck & Co., Inc. Method of inducing an enhanced immune response against hiv
WO2005014654A2 (en) * 2003-08-12 2005-02-17 Avidis Sa Product comprising a c4bp core protein and a monomeric antigen, and its use
WO2005051414A1 (en) * 2003-11-26 2005-06-09 Avidis Sa Use of c4bp core region as a cd40 agonist
EP1795540A1 (en) * 2005-11-30 2007-06-13 Imaxio Multimeric complexes of antigens and an adjuvant

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105744950A (zh) * 2013-11-05 2016-07-06 巴法里安诺迪克有限公司 用于使用表达肿瘤抗原的痘病毒和免疫检查点抑制剂的拮抗剂和/或激动剂治疗癌症的组合疗法

Also Published As

Publication number Publication date
WO2008122817A2 (en) 2008-10-16
US20110064768A1 (en) 2011-03-17
AU2008235315A1 (en) 2008-10-16
JP2010523138A (ja) 2010-07-15
GB0706912D0 (en) 2007-05-16
EP2155242A2 (en) 2010-02-24
WO2008122817A3 (en) 2008-12-11
CA2683117A1 (en) 2008-10-16

Similar Documents

Publication Publication Date Title
ES2638577T3 (es) Vectores adenovirales que codifican un patógeno o antígeno tumoral
EP1573012B1 (en) Recombinant viral-based malaria vaccines
JP7579298B2 (ja) 抗マラリアワクチンとしてのバイオ融合タンパク質
EP0979284B1 (en) Reagents for vaccination which generate a cd8 t cell immune response
US8470560B2 (en) CR-2 binding peptide P28 as molecular adjuvant for DNA vaccines
US12329808B2 (en) Compositions and methods for generating an immune response to treat or prevent malaria
AU2006284756A2 (en) Adenoviral vector-based malaria vaccines
CN101959420A (zh) 免疫原性组合物
WO2012114125A2 (en) Treatment and prevention of malaria
EP3209325A2 (en) Pfrh5 derived antigen for treatment of malaria
US20100278870A1 (en) Adenoviral vector-based malaria vaccines
Bruder et al. Molecular vaccines for malaria
CN1708587B (zh) 作为抗恶性疟的潜在疫苗的重组mva株
JP7649504B2 (ja) マラリアワクチン及びマラリア予防・治療方法
ES2377964T3 (es) Vacunas contra la malaria basadas en virus recombinante
US11013791B2 (en) NYVAC-based plasmodium malaria vaccine
WO2014188212A2 (en) Treatment and prevention of malaria
US9254316B2 (en) Adenoviral vector-based malaria vaccines
Nussenzweig et al. Plasmodium yoelii
Nogueira et al. Recombinant Yellow Fever Viruses Elicit CD8+ T Cell Responses and
CN102575256A (zh) 编码间日疟原虫抗原的经遗传修饰的序列

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20110126